the ADBL report

Issue #133, July 2023

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross

The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

In this issue:

Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on May 18, 2023. The Committee reviewed Manufacturer submissions for twenty-one (21) Drug Products for potential listing, or change in listing, on the *ADBL*. The Committee also considered information for a number of supplementary assessments of the coverage status of two (2) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, thirteen (13) Drug Products and Devices underwent Expedited Review for listing on the *ADBL* effective June 1, 2023, and eleven (11) Drug Products and Devices underwent Expedited Review for listing on the *ADBL* effective July 1, 2023.

The following are highlights of recent changes to the *ADBL* and other topics of general interest. A complete list of changes, as well as the full *ADBL* may be accessed at https://www.ab.bluecross.ca/dbl/publications.php

Highlights of Products Originally Reviewed by the Canadian Agency for Drugs and Technologies in Health (CADTH)

The following Drug Products were reviewed by CADTH and the Expert Committee and added to the *ADBL* effective June 1, 2023:

- **BEOVU* 6 mg/0.05 mL injection syringe** (brolucizumab) (NOV) via Restricted Benefit for the indication of Diabetic Macular Edema (DME)
- **DUPIXENT* 200 mg & 300 mg injection syringes** dupilumab) (SAV) via SA for the indication of Asthma ages 6-11

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.php.
Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*

ABC 81171 (07/2023)

- **DUPIXENT* 200 mg & 300 mg injection pens and injection syringes** (dupilumab) (SAV) via SA for the indication of Asthma ages 12+
- **GIVLAARI* 189 mg/mL injection** (givosiran sodium) (ANT) via Special Authorization (SA)

The following Drug Products were reviewed by CADTH and the Expert Committee and added to the *ADBL* effective July 1, 2023:

- **FIRDAPSE* 10 mg tablet** (amifampridine phosphate) (KYE) via SA

Highlights of Interchangeable (IC) Drug Products Added

Addition of the following Entry IC Drug Products to the *ADBL* has resulted in the creation of New IC Groupings, effective July 1, 2023:

- **SANDOZ ALFACALCIDOL 0.25 mcg & 1 mcg capsules** (alfacalcidol) (SDZ)

Highlights of Biosimilar Drug Products Added

The following Biosimilar Drug Product was added to the *ADBL* effective June 1, 2023:

- **ABRILADA 20 mg/0.4 mL injection syringe** (adalimumab) (PFI) via SA for the indication of Polyarticular Juvenile Idiopathic Arthritis (pJIA)

Special Authorization Criteria Changes

The Special Authorization criteria for coverage for the following Drug Products have been revised effective June 1, 2023:

- **DUPIXENT* 200 mg & 300 mg injection pens and injection syringes** (dupilumab) (SAV) for the indication of Atopic Dermatitis (AD)

The Special Authorization criteria for coverage for the following Drug Product has been revised effective July 1, 2023:

- **RUZURGI* 10 mg tablet** (amifampridine) (MDK)

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.html.
Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*
ABC 81171 (07/2023)